Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen NV

www.qiagen.com

Latest From Qiagen NV

Tech Transfer Roundup: MD Anderson Inks Set Of IO Deals Covering US, UK, Japan, China

Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.

Deals Research and Development Strategies

Global Approvals Snapshot: November 2019

November’s approvals include the US FDA approval of Medtronic’s In.Pact AV paclitaxel-coated balloon, for the treatment of arteriovenous access in patients with end-stage renal disease, and a CE mark that expands the indication for Edwards’ Sapien 3 TAVR device to include patients at low-risk during surgery.

Approvals Clinical Trials

Qiagen In Crisis, Previews Poor Q3 Sales; Long-Term CEO Steps Down

Qiagen shares took a hit following a series of negative announcements, including lower than expected results for Q3 2019 and the departure of long-term CEO Peer Schatz. The company said it had been affected by poor sales growth in China.

Sales & Earnings In Vitro Diagnostics

Novartis CEO Calms Concerns Over Zolgensma launch

The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.

Launches Sales & Earnings
See All

Company Information

UsernamePublicRestriction

Register